SPP1 and neoplasm: In the last 2 decades, OPN has been proposed to serve as a biomarker of tumor progression and metastasis, including in breast, lung, gastric, colon, hepatic and prostate carcinomas16,25–29, with the circulating osteopontin reported to be a dual marker of bone destruction and angiogenesis in multiple myeloma30.